In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...

• Ultra-low PSA Response (<0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes Interactive Poster Session: IP26-07; April 29, 9:30-11:30 a.m. PDT ...

Assessing patient-reported outcomes in urology is crucial for understanding clinical results and patient satisfaction. For inflatable penile prosthesis (IPP), satisfaction plays a key role in ...

The treatment of renal cell carcinoma (RCC), a malignancy that is typically chemoresistant, has drastically evolved with the introduction of vascular endothelial growth factor receptor tyrosine kinase ...

Prostate cancer is the most prevalent cancer among men worldwide, and there have been many advances in its diagnosis and treatment. However, critical obstacles remain, including overdiagnosis, high ...

Prostate-specific membrane antigen (PSMA) has been shown to be overexpressed in the neo-vasculature of renal cancers. However, studies investigating the pattern of PSMA expression in primary RCC and ...

Many preclinical hypotheses, including reciprocal feedback activation between AR-PI3K pathway in PTEN loss and ASI-induced "BRCAness" regardless of BRCA1/2 status, have struggled to translate into ...

How are we Getting Paid for Theranostics and Dosimetry? "Presentation" - Denise Merlino ...

Dry Mouth Prevention and Management for PSMA Radioligand Therapy "Presentation" - Sue Yom ...

To evaluate the diagnostic performance of a fully automated, commercially available AI algorithm for detecting prostate cancer and classifying lesions according to PI-RADS. In this retrospective ...